Plasma free amino acid profiling of five types of cancer patients and its application for early detection

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Miyagi, Yohei ^a   Higashiyama, Masahiko ^b   Gochi, Akira ^c   Akaike, Makoto ^a   Ishikawa, Takashi ^d   Miura, Takeshi ^a   Saruki, Nobuhiro ^e   Bando, Etsuro ^f   Kimura, Hideki ^g   Imamura, Fumio ^b   Moriyama, Masatoshi ^h   Ikeda, Ichiro ⁱ   Chiba, Akihiko ^a   Oshita, Fumihiro ^a   Imaizumi, Akira ^j   Yamamoto, Hiroshi ^j   Miyano, Hiroshi ^j   Horimoto, Katsuhisa ^k   Tochikubo, Osamu ^l   Mitsushima, Toru ^m   Yamakado, Minoru ⁿ   Okamoto, Naoyuki ^a   more..

^a KANAGAWA CANCER CENTER   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^e GUNMA PREFECTURAL CANCER CENTER   (Japan)

^f Shizuoka Prefectural Cancer Center   (Japan)

^g Chiba Prefecture Cancer Center   (Japan)

^h YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

ⁱ Yokohama Minami Kyosai Hospital   (Japan)

^j AJINOMOTO CO INC   (Japan)

^k NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^l Kanagawa Health Service Association   (Japan)

^m KAMEDA MEDICAL CENTER   (Japan)

ⁿ MITSUI MEMORIAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; FATTY ACID;

ADULT; AGED; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; STOMACH CANCER; VALIDATION PROCESS; ANALYSIS OF VARIANCE; BLOOD; MIDDLE AGED; NEOPLASM;

AGED; ANALYSIS OF VARIANCE; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 80052526020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024143     Document Type: Article

References (53)

1. Couzin J, (2009) Biomarkers. Metabolite in urine may point to high-risk prostate cancer. Science 323: 865.
2. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, et al. (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 3: e3694.
3. Kim Y, Koo I, Jung BH, Chung BC, Lee D, (2010) Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics 11 (Suppl 2): S4.
4. Nevedomskaya E, Ramautar R, Derks R, Westbroek I, Zondag G, et al. (2010) CE-MS for metabolic profiling of volume-limited urine samples: application to accelerated aging TTD mice. J Proteome Res 9: 4869-4874.
5. Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, et al. (2010) Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res 9: 2988-2995.
6. Tiziani S, Lopes V, Gunther UL, (2009) Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 11: 269-276, 264p following 269.
7. Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H, (2011) Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol 5: 281-291.
8. Roth C, Rack B, Muller V, Janni W, Pantel K, et al. (2010) Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 12: R90.
9. Abate-Shen C, Shen MM, (2009) Diagnostics: The prostate-cancer metabolome. Nature 457: 799-800.
10. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, et al. (2010) Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 70: 8309-8318.
11. Bictash M, Ebbels TM, Chan Q, Loo RL, Yap IK, et al. (2010) Opening up the "Black Box": metabolic phenotyping and metabolome-wide association studies in epidemiology. J Clin Epidemiol 63: 970-979.
12. Chadeau-Hyam M, Ebbels TM, Brown IJ, Chan Q, Stamler J, et al. (2010) Metabolic profiling and the metabolome-wide association study: significance level for biomarker identification. J Proteome Res 9: 4620-4627.
13. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, et al. (2009) Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 69: 4918-4925.
14. Slupsky CM, Steed H, Wells TH, Dabbs K, Schepansky A, et al. (2010) Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 16: 5835-5841.
15. Blaise BJ, Shintu L, Elena B, Emsley L, Dumas ME, et al. (2009) Statistical recoupling prior to significance testing in nuclear magnetic resonance based metabonomics. Anal Chem 81: 6242-6251.
16. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, et al. (2006) Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 66: 10795-10804.
17. Rubtsov DV, Waterman C, Currie RA, Waterfield C, Salazar JD, et al. (2010) Application of a Bayesian deconvolution approach for high-resolution (1)H NMR spectra to assessing the metabolic effects of acute phenobarbital exposure in liver tissue. Anal Chem 82: 4479-4485.
18. Felig P, Marliss E, Ohman JL, Cahill CF Jr, (1970) Plasma amino acid levels in diabetic ketoacidosis. Diabetes 19: 727-728.
19. Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, et al. (1976) The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery 80: 77-91.
20. Holm E, Sedlaczek O, Grips E, (1999) Amino acid metabolism in liver disease. Curr Opin Clin Nutr Metab Care 2: 47-53.
21. Hong SY, Yang DH, Chang SK, (1998) The relationship between plasma homocysteine and amino acid concentrations in patients with end-stage renal disease. J Ren Nutr 8: 34-39.
22. Cascino A, Muscaritoli M, Cangiano C, Conversano L, Laviano A, et al. (1995) Plasma amino acid imbalance in patients with lung and breast cancer. Anticancer Res 15: 507-510.
23. Heber D, Byerly LO, Chlebowski RT, (1985) Metabolic abnormalities in the cancer patient. Cancer 55: 225-229.
24. Kubota A, Meguid MM, Hitch DC, (1992) Amino acid profiles correlate diagnostically with organ site in three kinds of malignant tumors. Cancer 69: 2343-2348.
25. Lai HS, Lee JC, Lee PH, Wang ST, Chen WJ, (2005) Plasma free amino acid profile in cancer patients. Semin Cancer Biol 15: 267-276.
26. Norton JA, Gorschboth CM, Wesley RA, Burt ME, Brennan MF, (1985) Fasting plasma amino acid levels in cancer patients. Cancer 56: 1181-1186.
27. Proenza AM, Oliver J, Palou A, Roca P, (2003) Breast and lung cancer are associated with a decrease in blood cell amino acid content. J Nutr Biochem 14: 133-138.
28. Vissers YL, Dejong CH, Luiking YC, Fearon KC, von Meyenfeldt MF, et al. (2005) Plasma arginine concentrations are reduced in cancer patients: evidence for arginine deficiency? Am J Clin Nutr 81: 1142-1146.
29. Maeda J, Higashiyama M, Imaizumi A, Nakayama T, Yamamoto H, et al. (2010) Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer 10: 690.
30. Okamoto N, Miyagi Y, Chiba A, Akaike M, Shiozawa M, et al. (2009) Diagnostic modeling with differences in plasma amino acid profiles between non-cachectic colorectal/breast cancer patients and healthy individuals. Int J Med Med Sci 1: 1-8.
31. Kimura T, Noguchi Y, Shikata N, Takahashi M, (2009) Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks. Curr Opin Clin Nutr Metab Care 12: 49-53.
32. Noguchi Y, Zhang QW, Sugimoto T, Furuhata Y, Sakai R, et al. (2006) Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. Am J Clin Nutr 83: 513S-519S.
33. Zhang Q, Takahashi M, Noguchi Y, Sugimoto T, Kimura T, et al. (2006) Plasma amino acid profiles applied for diagnosis of advanced liver fibrosis in patients with chronic hepatitis C infection. Hepatol Res 34: 170-177.
34. Shimbo K, Kubo S, Harada Y, Oonuki T, Yokokura T, et al. (2009) Automated precolumn derivatization system for analyzing physiological amino acids by liquid chromatography/mass spectrometry. Biomed Chromatogr 24: 683-691.
35. Shimbo K, Oonuki T, Yahashi A, Hirayama K, Miyano H, (2009) Precolumn derivatization reagents for high-speed analysis of amines and amino acids in biological fluid using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 23: 1483-1492.
36. Shimbo K, Yahashi A, Hirayama K, Nakazawa M, Miyano H, (2009) Multifunctional and highly sensitive precolumn reagents for amino acids in liquid chromatography/tandem mass spectrometry. Anal Chem 81: 5172-5179.
37. Hanley JA, McNeil BJ, (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
38. Sobin L, Wittekind C, eds. (2002) TNM Classification of Malignant Tumours, Sixth Edition New York Wiley-Liss.
39. Jewett HJ, (1975) The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2: 105-124.
40. Borgan E, Sitter B, Lingjaerde OC, Johnsen H, Lundgren S, et al. (2010) Merging transcriptomics and metabolomics- advances in breast cancer profiling. BMC Cancer 10: 628.
41. Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humpfer E, et al. (2010) Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res 9: 319-332.
42. Urayama S, Zou W, Brooks K, Tolstikov V, (2010) Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 24: 613-620.
43. Qiu Y, Cai G, Su M, Chen T, Zheng X, et al. (2009) Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 8: 4844-4850.
44. Bossola M, Tazza L, Luciani G, (2009) Mechanisms and treatment of anorexia in end-stage renal disease patients on hemodialysis. J Ren Nutr 19: 2-9.
45. Morrison WL, Gibson JN, Rennie MJ, (1988) Skeletal muscle and whole body protein turnover in cardiac cachexia: influence of branched-chain amino acid administration. Eur J Clin Invest 18: 648-654.
46. Polge A, Bancel E, Bellet H, Strubel D, Poirey S, et al. (1997) Plasma amino acid concentrations in elderly patients with protein energy malnutrition. Age Ageing 26: 457-462.
47. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, et al. (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58: 153-157.
48. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P, (2009) Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 9: 445-452.
49. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC, (2005) Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319.
50. Zamanakou M, Germenis AE, Karanikas V, (2007) Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 111: 69-75.
51. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, et al. (2009) Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 7: 38.
52. Lotze MT, DeMarco RA, (2003) Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs 4: 1405-1409.
53. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ, (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388.